Restless Legs Syndrome Market - Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

The Restless Legs Syndrome Market is segmented by Type (Primary Restless Legs Syndrome, Secondary Restless Legs Syndrome), Treatment Type (Medication and Devices, Surgery), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

restless legs syndrome market
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 3.7 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The restless legs syndrome market is expected to register a CAGR of 3.7% over the forecast period, 2022-2027.

The outbreak of COVID-19 has many effects, such as travel bans, flight cancellations, supply chain disruption, stock market unpredictability, falling business assurance, growing panic among the population, and uncertainty about the future had a great impact on the life of the individual. People with restless legs syndrome showed an increase in symptom severity in the early phase of the COVID-19 pandemic in the United States in 2020. For Instance, as per the Kaiser Family Foundation report 2021, The COVID-19 pandemic has negatively affected individuals' mental health resulting in economic recession and new barriers for people already suffering from mental illness. As per the same source, during the pandemic, about 4 in 10 adults in the United States have reported symptoms of anxiety or depression.

The rise in the prevalence of restless legs syndrome is a key factor responsible for the growth of the market. According to a study published by Frontiers Media S.A., titled 'Restless Legs Syndrome Prevalence and Clinical Correlates Among Psychiatric Inpatients: A Multicenter Study in March 2022, the reported prevalence of restless legs syndrome varied between 3.9% and 14.3%. According to the same study, the prevalence of restless legs syndrome was high among females compared to males. According to another study published in eClinicalMedicine 2022, about 25% of people with diabetes showed signs of restless legs syndrome, and people with diabetes had an increased risk of developing restless legs syndrome as compared to people without diabetes. For Instance, According to the data published by the Centers for Disease Control and Prevention 2022, 37.3 million people in the United States have diabetes which is approximately 11.3% of the United States population.

Additionally, according to the data published by Tommy’s, a registered charity in England and Wales, in 2020, nearly 20% of pregnant women develop restless legs syndrome, most probably in the third trimester of pregnancy, caused by a change in hormones. Thus, due to the above-mentioned factors, the demand for the drugs is expected to increase, thereby driving the restless legs syndrome market over the forecast period.

Scope of the Report

Restless legs syndrome (RLS) is a situation that causes an uncontrollable urge to move the legs, usually because of an uncomfortable sensation. The Restless Legs Syndrome Market is segmented by Type (Primary Restless Legs Syndrome, Secondary Restless Legs Syndrome), Treatment Type (Medication and Devices, Surgery), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Type
Primary Restless Legs Syndrome
Secondary Restless Legs Syndrome
By Treatment Type
Medication and Devices
Dopamine Agonists
Anti-seizure Agent
Benzodiazepines
Opioids
Others
Surgery
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Primary Restless Legs Syndrome Segment is Expected to Hold a Major Market Share Over the Forecast Period

Primary restless leg syndrome is also known as idiopathic RLS, which means the cause is unknown. There is no single definitive test for restless leg syndrome, but the condition is usually diagnosed by looking at a variety of clinical markers such as involuntary leg movements and response to dopamine-enhancing medications. The increase in the prevalence of primary restless legs syndrome is anticipated to create the demand for primary restless legs syndrome treatment, thereby driving the segment market growth over the forecast period. For instance, as per the research study published in Annals of Thoracic Medicine 2020, primary restless legs syndrome is more prevalent than secondary restless legs syndrome.

The rising work-related stress caused due to the pressure on the nervous system is expected to be a major cause of primary restless legs syndrome. For instance, as per the Health and Safety Executive  2020-21 data, in Great Britain, the total number of cases associated with work-related stress, depression, or anxiety was around 822,000, and about 850,000 workers suffering from a new case of work-related ill health in 2020/21.

Estimated Number (in million) of People Living with Diabetes, Global, 2030 and 2045

North America is Expected to Dominate the Global Restless Legs Syndrome Market

North America dominated the restless legs syndrome market due to the rising prevalence of restless legs syndrome in the region. As per the data published by the sleep foundation in 2022, restless legs syndrome affects 5 to 10% of adults and 2 to 4% of children in the United States, and it is more prevalent in women than men. 

As per the American Association of Neuromuscular & Electrodiagnostic Medicine 2022, there are about 12 million people in the United States may have restless legs syndrome. Restless legs syndrome has a high prevalence in central Europe and North America, with a prevalence rate of about 5-15% as per the research study published in the Journal of Communication biology 2020. According to the research data published by Neurology and Neurosurgery 2020, it was found that 5% of the United States population and 10% of the population whose age was over 65 years have the problem of restless legs syndrome.

restless legs syndrome industry

Competitive Landscape

The restless legs syndrome market is fragmented and consists of several major players. Some of the companies which are currently dominating the market are Arbor Pharmaceuticals, LLC., Glenmark Pharmaceutical, UCB S.A., Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International GmbH, and Relegs, Restiffic, Viatris Inc., Psychocare Health Private Limited, and Noctrix Health, Inc.

Recent Development

  • In March 2022, Emalex Biosciences, Inc. entered into a license agreement with East Carolina University. Under the agreement, Emalex has licensed the patent rights of ecopipam (EBS-101), an investigational, first-in-class dopamine-1 (D1) receptor antagonist, to potentially advance clinical studies for the treatment of Restless Legs Syndrome with augmentation (RLSa).
  • In June 2021, a new observational study by the non-profit research institute RTI International found that individuals have a significantly higher likelihood of developing restless legs syndrome (RLS) when consuming medications commonly used to reduce acid reflux.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in Prevalence of Restless Leg Syndrome

      2. 4.2.2 High Unmet Need of Treatment and Increasing Geriatric Population

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects Associated with Restless Syndrome Treatments

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Type

      1. 5.1.1 Primary Restless Legs Syndrome

      2. 5.1.2 Secondary Restless Legs Syndrome

    2. 5.2 By Treatment Type

      1. 5.2.1 Medication and Devices

        1. 5.2.1.1 Dopamine Agonists

        2. 5.2.1.2 Anti-seizure Agent

        3. 5.2.1.3 Benzodiazepines

        4. 5.2.1.4 Opioids

        5. 5.2.1.5 Others

      2. 5.2.2 Surgery

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Arbor Pharmaceuticals, LLC

      2. 6.1.2 UCB S.A

      3. 6.1.3 Sun Pharmaceutical Industries Ltd

      4. 6.1.4 Boehringer Ingelheim International GmbH

      5. 6.1.5 Relegs

      6. 6.1.6 Restiffic

      7. 6.1.7 Viatris Inc

      8. 6.1.8 Psychocare Health Private Limited

      9. 6.1.9 Glenmark Pharmaceutical

      10. 6.1.10 Noctrix Health, Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Restless Legs Syndrome Market market is studied from 2019 - 2027.

The Global Restless Legs Syndrome Market is growing at a CAGR of 3.7% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Arbor Pharmaceuticals, LLC. , UCB S.A, Sun Pharmaceutical Industries Ltd , Boehringer Ingelheim International GmbH , Relegs are the major companies operating in Global Restless Legs Syndrome Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!